Mast Cell Activating Peptides as Vaccine Adjuvants
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adjuvants used in vaccine development, such as alum and Freund's complete adjuvant, pose safety concerns and are not effective in inducing strong immune responses, while chemical mast cell activators like compound 48/80 are complex mixtures with unknown active species, making them unsuitable for human use.
Innovation Solution
Development of isolated peptides, specifically mast cell activating peptides (MCAPs) of specific formulas, which are used in combination with immunogens to enhance immune responses by activating mast cells, thereby acting as adjuvants in vaccine compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If alum is used as an adjuvant, then safety is improved, but immune response strength deteriorates
Solution Approach 1:
The patent changes the chemical parameters of adjuvants by using peptide-based molecules with specific amino acid sequences (Formula I and Formula II) that have defined molecular weights, charges, and structures. This transitions from traditional inorganic adjuvants like alum to peptide-based adjuvants that can be precisely engineered for optimal immune stimulation while maintaining safety profiles.
Solution Approach 2:
The patent creates composite vaccine formulations by combining immunogens with peptide adjuvants of specific formulas. These composite materials integrate the antigenic properties of immunogens with the immunostimulatory properties of mast cell activating peptides, achieving enhanced immune responses without the limitations of traditional single-component adjuvants.
2Productivity
If Freund's complete adjuvant is used, then immune response strength is improved, but safety deteriorates
Solution Approach 1:
The patent extracts and isolates the beneficial immunostimulatory component (mast cell activating activity) from complex adjuvant systems like Freund's complete adjuvant. By identifying and utilizing specific peptide sequences that activate mast cells, the invention separates the desired immune-enhancing effect from the harmful necrotic and toxic components of traditional adjuvants.
Solution Approach 2:
The patent employs synthetic peptides with defined sequences that can be produced through solid-phase peptide synthesis. These peptides are designed to be used at low concentrations and are replaced after a single use, avoiding the accumulation of toxic residues associated with traditional adjuvants while providing potent, transient immune stimulation.
3Productivity
If compound 48/80 is used as a mast cell activator, then adjuvant activity is improved, but manufacturing precision deteriorates
Solution Approach 1:
The patent segments the complex mixture of compound 48/80 into individual peptide components with specific amino acid sequences (Formula I and Formula II). By synthesizing and characterizing discrete peptide molecules, the invention isolates the active adjuvant species from the complex polymer mixture, enabling precise control over composition and activity.
Solution Approach 2:
The patent changes the compositional parameters from an undefined polymer mixture to precisely characterized peptides with specific molecular weights, amino acid sequences, and charges. This transformation enables exact control over the adjuvant's properties through defined peptide sequences while maintaining potent mast cell activating activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MCAPs induce significant immune responses, including the production of neutralizing antibodies, and are effective as adjuvants in nasal vaccine formulations, providing improved immune stimulation without the safety concerns of existing adjuvants.
Implementation Method 1
Mast cells carry abundant, specialized intracellular granules storing many pre-synthesized immune mediators such as TNF-α, histamine, and tryptase that can be rapidly released through a process known as degranulation.
Data Source
AI summary
Provided herein are peptides that have activity as mast cell activating proteins (MCAP), as well as compositions, adjuvant compositions, vaccines, and pharmaceutical formulations that include the peptides. Also provided are methods of using the peptides, including methods for eliciting an immune response to an immunogen in a mammal upon administration.